Frontier IP Group (AIM:FIPP), the university spinout commercialisation business, has raised £4 million of fresh funding from investors and directors, giving it breathing room to help move maturing portfolio companies towards funding, commercial and exit milestones.
The AIM-listed company said its placing closed at 12p per share, raising around £3.88 million through the issue of 32.3 million shares.
Directors also subscribed for just over 1.0 million shares, raising about £120,000, with chief executive Neil Crabb putting in £70,000.
A separate retail offer through BookBuild remains open and could raise up to a further £400,000 before expenses. It is expected to close at 5pm tomorrow (18 June), with eligible UK retail investors able to participate at the same 12p price.
The issue price represented a 29.4% discount to the 17p closing mid-market share price on 15 June.
It follows Frontier IP’s warning in March that, as of 31 December 2025, it did not have enough cash to cover operating expenditure for 12 months, without portfolio realisations, and, that without further funding it expected the cash runway to run-out by the third quarter.
Now, however, the new proceeds are intended to strengthen the incubator's balance sheet, provide working capital, support near-term portfolio milestones and potential realisations. It also allows Frontier IP to selectively back portfolio companies and continue development of its SC² facility.
“This fundraising will support Frontier IP in delivering on the significant value we see in our maturing portfolio,” Neil Crabb said.
“We were very pleased to receive support from a wide range of existing and new investors in a challenging market.”
The first tranche, covering 6.9 million firm placing shares, is expected to start trading on AIM on 23 June. The remaining conditional placing shares, director subscription shares and any retail offer shares are expected to be admitted on 16 July, subject to shareholder approval at a general meeting on 15 July.
Frontier IP noted that its six core holdings (2D Photonics, Pulsiv, Alusid, The Vaccine Group, Cambridge Raman Imaging and GraphEnergyTech) represented more than two-thirds of its total portfolio fair value of £35.9 million at 31 December 2025.
